The potential of swine pseudorabies virus attenuated vaccine for oncolytic therapy against malignant tumors

BACKGROUND: Oncolytic viruses are now well recognized as potential immunotherapeutic agents against cancer. However, the first FDA-approved oncolytic herpes simplex virus 1 (HSV-1), T-VEC, showed limited benefits in some patients in clinical trials. Thus, the identification of novel oncolytic viruse...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Guosong, Cao, Jiali, Gui, Mengxuan, Huang, Pengfei, Zhang, Liang, Qi, Ruoyao, Chen, Ruiqi, Lin, Lina, Han, Qiangyuan, Lin, Yanhua, Chen, Tian, He, Peiqing, Ma, Jian, Fu, Rao, Hong, Junping, Wu, Qian, Yu, Hai, Chen, Junyu, Huang, Chenghao, Zhang, Tianying, Yuan, Quan, Zhang, Jun, Chen, Yixin, Xia, Ningshao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604416/
https://www.ncbi.nlm.nih.gov/pubmed/37891570
http://dx.doi.org/10.1186/s13046-023-02848-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604416/
https://www.ncbi.nlm.nih.gov/pubmed/37891570
http://dx.doi.org/10.1186/s13046-023-02848-1

Ejemplares similares